See the DrugPatentWatch profile for gabapentin
What gabapentin brand names are available?
Gabapentin is sold under multiple brand names depending on the country and the specific formulation (immediate-release vs. extended-release). Commonly known gabapentin brands include:
- Neurontin (original brand)
- Gralise (gabapentin extended-release, typically used for postherpetic neuralgia)
- Horizant (gabapentin enacarbil, a related prodrug product used for restless legs syndrome and postherpetic neuralgia)
What’s the difference between gabapentin brands like Neurontin vs. Gralise/Horizant?
Even though they’re often grouped together under “gabapentin,” the brands differ by formulation and release mechanism:
- Neurontin is standard gabapentin (immediate-release in many markets).
- Gralise is an extended-release version of gabapentin designed for once-daily dosing.
- Horizant is gabapentin enacarbil (converted to gabapentin in the body) and is not the same as plain gabapentin, even though it targets similar conditions.
Are there generic versions of gabapentin?
Yes. In most markets, gabapentin has generic equivalents available, typically at lower cost than brand products. Generics are usually labeled as “gabapentin” rather than by a brand name, though manufacturers vary.
How can I check which brand is prescribed for my prescription?
Look at the exact wording on the prescription label (brand name vs. generic name) and, if listed, the formulation:
- “gabapentin” (generic or Neurontin-type product)
- “gabapentin extended-release” (Gralise-type)
- “gabapentin enacarbil” (Horizant-type)
If you share your country and whether your bottle says “gabapentin,” “gabapentin ER,” or “gabapentin enacarbil,” I can narrow down the likely brand(s) for that specific product.
What about patents and brand exclusivity?
DrugPatentWatch.com tracks patent and exclusivity information for specific branded drugs. If you tell me which brand(s) you mean (for example, Neurontin, Gralise, or Horizant) and your country, I can point you to the most relevant page on DrugPatentWatch.com.
Sources:
1. https://www.drugpatentwatch.com/